WebDoctor Encyclopedia

Lymphomas

Primary mediastinal large B-cell lymphoma (PMBCL)

Primary mediastinal large B-cell lymphoma (PMBCL) is a fast-growing B-cell lymphoma that starts in the thymus area of the chest. It mainly affects young women and is usually curable.

Medically reviewed Last reviewed October 21, 2026

What is primary mediastinal large B-cell lymphoma?

Primary mediastinal large B-cell lymphoma (PMBCL) is a fast-growing type of non-Hodgkin lymphoma. It starts in the mediastinum, the space in the middle of the chest behind the breastbone and between the lungs.

It develops from B lymphocytes that live in the thymus, a small gland in the chest. For this reason it is also called primary mediastinal (thymic) large B-cell lymphoma.

PMBCL mainly affects young adults, especially women in their 20s and 30s. It usually causes a large mass in the chest that can press on the airways and the big veins returning blood to the heart.

Although it was once grouped with diffuse large B-cell lymphoma (DLBCL), PMBCL is now known to be a separate disease. In its biology, it has much in common with classic Hodgkin lymphoma.

The outlook is very good. With modern chemoimmunotherapy, around 85-95% of people are cured.

1. Key facts at a glance

Feature Details
How common About 2-4% of non-Hodgkin lymphomas and about 6-10% of large B-cell lymphomas
Typical age Median age about 35; most patients are 20-40
Sex More common in women (about 2 to 1)
Site Anterior mediastinum (front of the chest)
Typical size Often over 10 cm (bulky) at diagnosis
Key biology Gains of chromosome 9p24.1, raising PD-L1 and PD-L2; activated JAK-STAT and NF-kappaB pathways
Main treatment Rituximab-based chemotherapy (DA-EPOCH-R or R-CHOP), with radiotherapy for some
Outlook Long-term survival about 85-95%

2. Causes and biology

The cause of PMBCL is unknown. It is not inherited and not contagious, and no lifestyle cause has been found.

The lymphoma cells carry characteristic acquired gene changes:

Change Effect
9p24.1 gain or amplification Increases PD-L1 and PD-L2, proteins that switch off immune attack. This is why PD-1 blocking drugs work in relapsed PMBCL
JAK-STAT activation Changes in JAK2, SOCS1 and STAT6 drive cell growth
NF-kappaB activation Supports cell survival
CIITA changes Reduce MHC molecules on the cell surface, helping the lymphoma hide from the immune system

These changes are shared with nodular sclerosis classic Hodgkin lymphoma. Rare tumours with features of both are called mediastinal grey zone lymphoma.

3. How does it look?

3.1 On the body

Most of the changes are inside the chest, but some can be seen:

Sign What it looks like
Swollen face and neck Puffiness, especially in the morning, from pressure on the superior vena cava
Swollen veins Prominent, widened veins on the neck, chest and upper arms
Red or purple face Particularly when bending forward or lying down
Swollen arms Fluid build-up in one or both arms
Lumps above the collarbone Enlarged lymph nodes in the lower neck in some people

3.2 On scans

Test Typical findings
Chest X-ray A widened mediastinum
CT scan A large, lobulated mass in the front of the chest, often over 10 cm. It may surround or compress the blood vessels and windpipe, invade the chest wall, lung or pericardium, and cause fluid around the lungs or heart
PET-CT Very high uptake of the tracer (FDG); used for staging and to judge response at the end of treatment

PMBCL usually stays in the chest. Spread to the bone marrow at diagnosis is uncommon. At relapse, it can spread to unusual places such as the kidneys, adrenal glands, liver, ovaries and the brain.

3.3 Under the microscope

Feature Description
Cells Medium to large B cells, often with clear (pale) cytoplasm
Fibrosis Bands of fibrous tissue divide the tumour into small compartments (compartmentalising sclerosis)
Markers CD20 and CD79a positive; often CD23, MAL and CD30 (usually weaker than in Hodgkin lymphoma); PD-L1 often positive
Negative markers Usually CD15 negative and no surface immunoglobulin, which helps to tell it apart from Hodgkin lymphoma

4. Symptoms

Symptoms develop over weeks to a few months, as the mass grows quickly.

4.1 Chest symptoms

Symptom Cause
Dry cough Pressure on the windpipe or airways
Breathlessness Pressure on the airways, fluid around the lungs, or pressure on the heart
Chest pain or tightness Mass pressing on surrounding structures
Swelling of the face, neck and arms, headache Superior vena cava syndrome, a common feature of PMBCL
Hoarse voice or difficulty swallowing Pressure on nerves or the gullet
Breathlessness lying flat Mass pressing on the airway when lying down

4.2 General symptoms

Symptom Details
B symptoms Fever, drenching night sweats and weight loss affect a minority
Tiredness Common

4.3 When to get urgent help

Get urgent medical help if you have:

Large chest masses can be risky during anaesthesia, so the biopsy is planned carefully, often using a CT-guided needle rather than general anaesthesia.

5. Diagnosis

Test Purpose
Biopsy CT-guided core needle biopsy or a minor surgical biopsy (mediastinoscopy or mediastinotomy); confirms the diagnosis
Immunohistochemistry Confirms the B-cell type and separates PMBCL from Hodgkin lymphoma, grey zone lymphoma, thymoma and germ cell tumour
PET-CT Staging and baseline for response
Blood tests Full blood count, LDH (often raised), liver and kidney function, HIV and hepatitis B and C tests
Heart scan (echocardiogram) Before anthracycline chemotherapy; also checks for fluid around the heart
Pregnancy test and fertility discussion Important because many patients are young

5.1 Staging

Most people have stage I or II disease, limited to the chest and neighbouring nodes. Doctors also note bulk (a mass of 10 cm or more), raised LDH and spread outside the lymph tissue, which affect the outlook.

6. Treatment

Treatment aims at cure and should be planned by an experienced lymphoma team.

6.1 First-line chemoimmunotherapy

Regimen Details
DA-EPOCH-R Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab, given over 6 cycles as a continuous infusion. In a US study, 93% were free of disease events and 97% alive at about 5 years, mostly without radiotherapy
R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone every 2 or 3 weeks, for 6 cycles. Often followed by radiotherapy if the end-of-treatment PET is positive
R-CHOP-14 or other intensified regimens Used in some European centres

6.2 Radiotherapy

Radiotherapy to the chest used to be routine. It increases the long-term risk of breast cancer, heart disease and lung damage, which matters in young women.

The IELSG37 trial (2024) showed that people whose PET scan shows a complete metabolic response after chemoimmunotherapy can safely skip radiotherapy, as outcomes were very similar with or without it. Radiotherapy is now mainly used when the PET scan shows remaining active disease.

6.3 Relapsed or refractory disease

About 10-15% of people do not respond or relapse, almost always within the first 12-18 months. Options include:

Option Details
CAR T-cell therapy Axicabtagene ciloleucel or lisocabtagene maraleucel; PMBCL patients were included in pivotal trials and respond well
PD-1 inhibitors Pembrolizumab is approved for relapsed PMBCL; in KEYNOTE-170, responses were often long-lasting
Nivolumab plus brentuximab vedotin In the CheckMate 436 trial, about 70% responded
Salvage chemotherapy and autologous stem cell transplant For chemotherapy-sensitive relapse
Allogeneic stem cell transplant Occasionally, after other options

6.4 Side effects of treatment

Treatment Main side effects
Chemotherapy Low blood counts and infections, hair loss, nausea, mouth sores, tingling in the hands and feet (vincristine), tiredness
Doxorubicin Heart damage in a small number, sometimes years later
Rituximab Infusion reactions; reactivation of hepatitis B
Radiotherapy Sore throat, cough; later, raised risk of breast cancer, heart disease and thyroid problems
PD-1 inhibitors Immune inflammation of the thyroid, skin, bowel, liver or lungs
CAR T cells Cytokine release syndrome (fever, low blood pressure) and neurological effects such as confusion
Fertility Chemotherapy may reduce fertility; egg, embryo or sperm storage can be discussed before treatment

7. Outlook (prognosis)

Situation Approximate outcome
After first-line treatment About 85-95% are cured
Complete metabolic response on end-of-treatment PET Very low risk of relapse
Relapse after 2 years Rare
Relapsed or refractory disease Historically poor; CAR T cells and PD-1 inhibitors now lead to long-term remission in a proportion of patients

8. Follow-up and late effects

What How often
Clinic review and blood tests Every 3 months for 2 years, then less often up to 5 years
Scans Not routinely after a negative end-of-treatment PET; done if symptoms appear
Heart checks Long-term, after anthracyclines or chest radiotherapy
Breast screening Earlier and more frequent for women who had chest radiotherapy before age 36
Thyroid tests Yearly after radiotherapy to the neck or upper chest

9. Special situations and daily life

Topic Key points
Pregnancy PMBCL is sometimes diagnosed in pregnancy because it affects young women. Chemotherapy can often be given safely in the second and third trimesters; a specialist team plans timing, delivery and imaging that avoids radiation
Superior vena cava syndrome Usually improves within days of starting chemotherapy and steroids; a stent or blood thinners are needed only occasionally
Work and study Many people continue some work or study during treatment, but tiredness is common, especially towards the end of chemotherapy
Infection precautions Report a temperature of 38 C or more straight away during chemotherapy
Vaccines Inactivated vaccines (such as flu and COVID-19) are recommended; live vaccines are avoided during and soon after treatment
Smoking Stopping smoking lowers the risk of lung and heart problems, especially after chest radiotherapy
Emotional support A cancer diagnosis in young adulthood can affect relationships, work and finances; counsellors, nurse specialists and charities can help

10. Frequently asked questions

Question Answer
Is PMBCL the same as Hodgkin lymphoma? No. Both often start in the chest of young adults and share some biology, but PMBCL is a B-cell non-Hodgkin lymphoma treated with different regimens
Why is my chest mass still visible after treatment? Scar tissue often remains. PET-CT shows whether it still contains active lymphoma
Will I need radiotherapy? Not if the end-of-treatment PET scan shows a complete metabolic response, based on current evidence
Can I have children after treatment? Many people do. Discuss fertility preservation with your team before starting chemotherapy
Can it come back? Relapse is uncommon and usually happens in the first 1-2 years; after that, the risk becomes very small

Resources

  1. Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
  2. Campo, E. et al. (2022) ‘The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee’, Blood, 140(11), pp. 1229-1253.
  3. Rosenwald, A. et al. (2003) ‘Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma’, Journal of Experimental Medicine, 198(6), pp. 851-862.
  4. Green, M.R. et al. (2010) ‘Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma’, Blood, 116(17), pp. 3268-3277.
  5. Dunleavy, K. et al. (2013) ‘Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma’, New England Journal of Medicine, 368(15), pp. 1408-1416.
  6. Rieger, M. et al. (2011) ‘Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study’, Annals of Oncology, 22(3), pp. 664-670.
  7. Dunleavy, K. (2017) ‘Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies’, Hematology: American Society of Hematology Education Program, 2017(1), pp. 298-303.
  8. Martelli, M. et al. (2024) ‘Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results’, Journal of Clinical Oncology, 42(34), pp. 4071-4083.
  9. Armand, P. et al. (2019) ‘Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma’, Journal of Clinical Oncology, 37(34), pp. 3291-3299.
  10. Zinzani, P.L. et al. (2023) ‘Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170’, Blood, 142(2), pp. 141-145.
  11. Zinzani, P.L. et al. (2019) ‘Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study’, Journal of Clinical Oncology, 37(33), pp. 3081-3089.
  12. Neelapu, S.S. et al. (2017) ‘Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma’, New England Journal of Medicine, 377(26), pp. 2531-2544.
  13. Abramson, J.S. et al. (2020) ‘Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study’, The Lancet, 396(10254), pp. 839-852.
  14. National Cancer Institute (2026) Adult Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.